- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03339037
Hyperbaric Oxygen Therapy Effect on Post Concussion Syndrome in Children (TBIPED)
Application of Hyperbaric Oxygen Therapy for Children Suffering From Prolonged Post-Concussion Syndrome Due to Mild Traumatic Brain Injury
Due its high incidence, mTBI and its consequences of PPCS are a major public health issue. There is no consensus regarding the treatment of PPCS in pediatrics. Relying on its results in adults, HBOT offers a promising new direction of treatment, which targets the basic pathological processes responsible for post-concussion symptoms.
The effect of hyperbaric oxygen therapy in pediatric TBI has never been evaluated.
The aim of the current study is to evaluate in a prospective cross-over, randomized study, the effect of HBOT on children with PPCS due to mild TBI.
Study Overview
Status
Intervention / Treatment
Detailed Description
The study is designed as a prospective, randomized, controlled, cross-over two groups trial. The study will be conducted in the -Sagol center for hyperbaric medicine and research and the children neurological unit of Assaf Harofeh Medical Center, Israel. Brain MRIs evaluation will be done the radiology department of Assaf-Harofeh Medical Center, Israel.
Study will include 70 patients After signing the informed consent (signed by the parents), patients will undergo computerized cognitive tests using the computerized Neurotrax and Moxo cognitive batteries. Patients who fulfill inclusion criteria will be included in the study.
After signing informed consent (by parents, at the prescreening phase), patients who fill inclusion criteria, will be randomized in 1:1 manner into the treated or the control-cross group. Randomization will be performed using a computer software according to patient id. After the randomization, patients will be invited for baseline evaluation that will include full review of their medical status and complete physical examination.
All patients will go through evaluation of their neurocognitive function using further neurocognitive testing battery, questionnaires and brain imaging (perfusion MRI+DTI, SPECT). In cases of brain tumors, skull base tumors, encephalomalacia findings in MRI, patients will be excluded.
The patients in the treated group will be evaluated three time - at baseline, after 3 months of HBOT treatment and after another consequent 3 months period from treatment (6 months from baseline). The patients of the cross group will be evaluated three times as well- at baseline, after 3 month control period without hyperbaric treatment and after a consequent 3 month period of HBOT treatment.
The following HBOT treatment protocol will be practiced: The patients will go through 60 HBOT treatments (each treatment session will be given on a separate day), distributed over three months (five days a week). Each session will be for 60 minutes in 100% oxygen atmosphere and at pressure of 1.5 ATA.
Study Type
Enrollment (Actual)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
-
Ẕerifin, Israel, 70300
- Assaf-Harofeh Medical Center
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- - Ages 8-15
- Mild TBI (defined as loss of consciousness with duration of 0-30 minutes, post-traumatic amnesia with duration of less than 24 hours, Glasgow Coma Scale grade of 13-15) within 6 months-3 years prior to the inclusion in the study.
- Moderate TBI -Patients with a GCS of 9-12 a as well as additional criteria such as CT abnormalities and admission to hospital
- Presence of at least two PCS as measured by the Post-Concussion Symptom Inventory )see attached) (there's a RCT now recruitingwith at least 1 and not 2) for at least 3 months.
- No change in cognitive or behavioral functions during one month prior to the beginning of the study (according to parents/teachers report).
Screening protocol:
After signing the informed consent (signed by the parents), patients will undergo computerized cognitive tests using the computerized Neurotrax in patients over 10, and standard pen and paper cognitive tests in patients under 10. Patients who fulfill inclusion criteria will be included in the study.
Inclusion criteria:
- Objective cognitive impairment: a decrease of at least 1 standard deviation (SD) from same age mean score in one or more of the following indices : memory, attention, information processing speed, executive functions in both Neurotrax
Exclusion Criteria:
- - Dynamic neurologic improvement or worsening during the past month (according to parents/teachers report);
- Had been treated with HBOT for any other reason prior to their inclusion;
- Chest pathology incompatible with pressure changes (including asthma)
- Inner ear disease;
- Claustrophobia;
- Inability to perform awake brain MRI test
- Previous neurologic conditions (eg. Epilepsy, neuromuscular diseases, metabolic diseases, etc.)
- Brain tumors
- Skull base fractures
- Active malignancy
- s/p neurosurgery that included: ventricular drainage, subdural hematomas drainage, epidural hematomas drainage, intracerebral hemorrhage evacuation. Depressed fracture surgery, won't be excluded.
- Encephalomalacia per MRI imaging
- No informed consent
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Crossover Assignment
- Masking: Quadruple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
|---|---|
|
Active Comparator: Hyperbaric oxygen therapy
60 Hyperbaric oxygen sessions in a multiplace hyperbaric chamber (HAUX-Life-Support GmbH). each session 1.5 ATA of 100% oxygen for 1 hour. 1 meter per minute compression and decompression. |
60 HBOT sessions at 2 ATA 100% oxygen
|
|
Sham Comparator: Normobaric air SHAM
60 sessions in a multiplace hyperbaric chamber (HAUX-Life-Support GmbH). Each session at 1 ATA of 21% oxygen (air) for 1 hour. 1 meter per minute compression and decompression. after 3 months, patients will be crossed over and treated with 60 sessions of treatment |
60 sessions at 1 ATA 21% oxygen (air)
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Cognitive function
Time Frame: at 3 months
|
General,Attention, Memory, Executive functions, Visual spatial and Verbal memory indices Index (scale 0-100) will be measured using the computerized standardized Neurotrax battery test.
Each of above cognitive indices is computed as a normalized combined score of 2-3 cognitive tests.
(At baseline, this battery will be conducted as part of the screening in patients over 10).
|
at 3 months
|
|
Cognitive function
Time Frame: at 6 months
|
General,Attention, Memory, Executive functions, Visual spatial and Verbal memory indices Index (scale 0-100) will be measured using the computerized standardized Neurotrax battery test.
Each of above cognitive indices is computed as a normalized combined score of 2-3 cognitive tests.
(At baseline, this battery will be conducted as part of the screening in patients over 10).
|
at 6 months
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Post concussion syndrome symptoms
Time Frame: baseline, 3 months and 6 months from baseline
|
Patients and their parents will fill questionaries' Postconcussion Symptom Inventory (PCSI) (scale 0-21) at baseline and at their second and/or third evaluations
|
baseline, 3 months and 6 months from baseline
|
|
Health Behaviour inventory
Time Frame: baseline, 3 months and 6 months from baseline
|
Patients and their parents will fill questionaries' Health Behaviour inventory (scale 50-200) at baseline and at their second and/or third evaluations
|
baseline, 3 months and 6 months from baseline
|
|
Balance
Time Frame: baseline, 3 months and 6 months from baseline
|
Patients will undergo balance tests (BERG Balance Scale) (scale 0-56) at each of the evaluations
|
baseline, 3 months and 6 months from baseline
|
|
Brain functional imaging
Time Frame: baseline, 3 months
|
Patients will undergo photon emission tomography (PET-CT) using FDG at each of the three evaluations
|
baseline, 3 months
|
|
Brain microstructural imaging
Time Frame: baseline, 3 months and 6 months from baseline
|
Imaging will be conducted in using a 3 Tesla system (Siemens, Germany).
The MRI protocol includes the following sequences: Axial T1, T2, FLAIR, Axial Diffusion weighted, Axial T1-PostGadollinium , dynamic contrast enhancement (DSC), diffusion tensor imaging (DTI)
|
baseline, 3 months and 6 months from baseline
|
|
Brain perfusion
Time Frame: baseline, 3 months and 6 months from baseline
|
Imaging will be conducted in using a 3 Tesla system (Siemens, Germany).
The MRI protocol includes the following sequences: Axial T1, T2, FLAIR, Axial Diffusion weighted, Axial T1-PostGadollinium , dynamic contrast enhancement (DSC), diffusion tensor imaging (DTI)
|
baseline, 3 months and 6 months from baseline
|
|
Brain network analysis
Time Frame: baseline, 3 months and 6 months from baseline
|
Patients will undergo resting state EEG as well as EEG during performing cognitive tasks ,using a 64 electrodes cap.
|
baseline, 3 months and 6 months from baseline
|
|
Behaviour
Time Frame: baseline, 3 months and 6 months from baseline
|
The parents and their teachers will complete the following questionnaire at baseline and at their second and/or third evaluations.
The rating scales are available for parent (Conners 3-P), teacher (Conners 3-T) and self-report (Conners 3-SR).Subscales include inattention, hyperactivity/impulsivity, learning, executive functioning, aggression and peer relations, as well as subscales mapping onto DSM-IV criteria for ADHD (inattentive), ADHD (hyperactive-impulsive), ADHD combined, Conduct Disorder, and Oppositional-Defiant Disorder.
Means and standard deviations for the global index vary dependent on age (for 6 year-olds the mean is 5.15 with a standard deviation of 3.97; means for 17 to 18 year-olds are 3.90 with a standard deviation of 4.00).
Raw scores are usually converted to T-scores or percentile scores relative to normative data.
T-scores above 60 (percentiles above 84) are considered clinically significant.
|
baseline, 3 months and 6 months from baseline
|
|
Executive functions
Time Frame: baseline, 3 months and 6 months from baseline
|
The parents and their teachers will complete the Behavior Rating Inventory of Executive Function(BRIEF) questionnaire at baseline and at their second and/or third evaluations. he Global Executive Composite (GEC) is an overarching summary score that incorporates all of the BRIEF clinical scales. The possible range of scores for teachers is 0 to 24. |
baseline, 3 months and 6 months from baseline
|
|
Short form health survey (PedsQL)
Time Frame: baseline, 3 months and 6 months from baseline
|
Patients and their parents will complete questionnaires Pediatric Quality of Life inventory (PedsQL) - multi-dimensional concept that includes domains related to physical, mental, emotional, and social functioning.
|
baseline, 3 months and 6 months from baseline
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Shai a Efrati, MD, Asaf-Harofhe MC
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Brain Diseases
- Central Nervous System Diseases
- Nervous System Diseases
- Wounds and Injuries
- Craniocerebral Trauma
- Trauma, Nervous System
- Head Injuries, Closed
- Wounds, Nonpenetrating
- Brain Injuries
- Brain Injuries, Traumatic
- Brain Concussion
- Post-Concussion Syndrome
- Therapeutics
- Respiratory Therapy
- Oxygen Inhalation Therapy
- Hyperbaric Oxygenation
Other Study ID Numbers
- 0120-16-ASF
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Traumatic Brain Injury
-
Fondazione per la Ricerca Ospedale MaggioreCompletedBrain Injuries, Traumatic | Brain Injury Traumatic Severe | Brain Injury Traumatic ModerateItaly
-
Hospital Sirio-LibanesUniversity of Sao Paulo; Ministry of Health, Brazil; Hospital Sao Rafael; PROAD... and other collaboratorsRecruitingBrain Injury Traumatic Severe | Brain Injury Traumatic Moderate | Post Traumatic EpilepsyBrazil
-
University of TurkuTurku University Hospital; The Finnish Funding Agency for Technology and Innovation... and other collaboratorsCompletedBrain Injuries | TBI (Traumatic Brain Injury) | Brain Injuries, Traumatic | Traumatic Brain Injury | Injury, Brain, TraumaticFinland
-
Institut National de la Santé Et de la Recherche...Institut National de Recherche en Informatique et en AutomatiqueRecruitingTBI (Traumatic Brain Injury)France
-
Children's Hospital Medical Center, CincinnatiUniversity of CincinnatiCompletedBrain Injury Traumatic MildUnited States
-
University of Texas Southwestern Medical CenterAlbert Einstein College of Medicine; National Institute of Neurological Disorders... and other collaboratorsRecruitingTBI (Traumatic Brain Injury) | TBI | Traumatic Brain Injury With Loss of Consciousness | Brain Injury Traumatic Severe | Brain Injury Traumatic ModerateUnited States
-
BrainScope Company, Inc.Active, not recruitingTBI (Traumatic Brain Injury) | Concussion, Brain | MTBI - Mild Traumatic Brain Injury | Closed Head InjuryUnited States
-
Toronto Rehabilitation InstituteCentre for Aging and Brain Health Innovation; Ontario Neurotrauma FoundationRecruitingBrain Injuries, Traumatic | Brain Injury, Chronic | Brain Injury Traumatic Severe | Brain Injury Traumatic ModerateCanada
-
University of Sao Paulo General HospitalUnknownTraumatic Brain Injury | Severe Brain Injury | Closed Traumatic Brain InjuryBrazil
-
Queen Mary University of LondonCompleted
Clinical Trials on Hyperbaric oxygen therapy
-
National Baromedical ServicesMayo Clinic; Dartmouth-Hitchcock Medical Center; Eastern Virginia Medical School and other collaboratorsCompletedCarcinoma, Squamous Cell | Cancer of the Head and NeckUnited States
-
Bayside HealthNational Health and Medical Research Council, Australia; Monash UniversityCompletedTibial Fracture | Soft Tissue InjuryAustralia, Sweden, Chile, United States, Austria, India, Italy, Portugal, Czechia
-
Louisiana State University Health Sciences Center...U.S. Army Medical Research and Development CommandUnknownTraumatic Brain Injury | Post-Concussion SyndromeUnited States
-
Second Affiliated Hospital, School of Medicine,...Not yet recruiting
-
Omar AljitawiCompleted
-
University of British ColumbiaUnknown
-
Jinan Central HospitalEnrolling by invitationBreast Cancer | Lung Metastasis | Hyperbaric Oxygen TherapyChina
-
Assaf-Harofeh Medical CenterTerminatedChronic Renal FailureIsrael
-
Erasmus Medical CenterDa Vinci Clinic; HGC RijswijkNot yet recruitingPost-COVID-19 Syndrome | Long COVID | Long Covid19 | Post COVID-19 Condition | Post-COVID Syndrome | Post COVID-19 Condition, Unspecified | Post-COVID ConditionNetherlands
-
Northwestern UniversityNational Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)RecruitingUlcerative ColitisUnited States